TG Therapeutics, Inc.
TGTX
$30.63
-$1.04-3.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.57% | 16.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.57% | 16.79% | |||
| Cost of Revenue | 48.34% | 21.86% | |||
| Gross Profit | 9.33% | 16.04% | |||
| SG&A Expenses | 14.01% | 10.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.49% | -5.28% | |||
| Operating Income | -15.72% | 304.12% | |||
| Income Before Tax | -16.21% | 465.47% | |||
| Income Tax Expenses | -13,454.77% | 569.85% | |||
| Earnings from Continuing Operations | 1,286.79% | 457.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1,286.79% | 457.06% | |||
| EBIT | -15.72% | 304.12% | |||
| EBITDA | -15.70% | 303.89% | |||
| EPS Basic | 1,299.32% | 456.81% | |||
| Normalized Basic EPS | -15.41% | 465.24% | |||
| EPS Diluted | 1,329.41% | 466.67% | |||
| Normalized Diluted EPS | -15.39% | 466.19% | |||
| Average Basic Shares Outstanding | -0.90% | 0.04% | |||
| Average Diluted Shares Outstanding | -0.96% | -0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||